Sino Biopharmaceutical-UnadrSBHMY
13F holders, Q3 2024 (September 30)1holders
0new positions
0sold out
$9.60avg. 13F price*
At the end of Q3 2024, 1 institutions reported holding Sino Biopharmaceutical-Unadr (SBHMY) in their 13F filings, unchanged from Q2 2024. 0 opened new positions and 0 sold out. The largest holder was Rhumbline Advisers ($85K).
- Company
- Sino Biopharmaceutical-Unadr
- CUSIP
- 82937X103
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Rhumbline Advisers | 0.00% | No change | 8,855 | $85K |
"% of holder's portfolio" is SBHMY's weight in each manager's 13F, not the share of Sino Biopharmaceutical-Unadr the manager owns.